<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04199741</url>
  </required_header>
  <id_info>
    <org_study_id>19-292</org_study_id>
    <nct_id>NCT04199741</nct_id>
  </id_info>
  <brief_title>PET/CT Imaging of Small Cell Lung Cancer Using 89Zr-DFO-SC16.56</brief_title>
  <official_title>Immuno-PET Imaging of Small Cell Lung Cancer Using 89Zr-DFO-SC16.56, a DLL3-Targeting Monoclonal Antibody</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Memorial Sloan Kettering Cancer Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Memorial Sloan Kettering Cancer Center</source>
  <oversight_info>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to look at how safe 89Zr-DFO-SC16.56 is, and how it is processed
      by the body in people with small cell lung cancer.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">December 11, 2019</start_date>
  <completion_date type="Anticipated">June 11, 2021</completion_date>
  <primary_completion_date type="Anticipated">June 11, 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Phase I: Radiation Dosimetry of 89Zr- DFO-SC16.56 PET/CT imaging in participants</measure>
    <time_frame>Up to 12 months</time_frame>
    <description>The PET and blood data are used to quantify tracer-biodistribution, measuring the amount of radioactivity present in the blood and bodily regions-of-interest</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Phase I: Safety of 89Zr- DFO-SC16.56 PET/CT imaging in cancer patients by evaluating toxicities</measure>
    <time_frame>up to 12 months</time_frame>
    <description>89Zr- DFO-SC16.56 PET/CT will be considered safe if there are no possibly probably, or definitely related grade 3 or higher toxicities (except allergic reactions) among the patients enrolled in the phase I portion</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Phase II: Correlation between tumor uptake of 89Zr- DFO-SC16.56 with expression of DLL3</measure>
    <time_frame>Up to 12 months</time_frame>
    <description>This is determined by immunohistochemistry and quantitative mass spectrometry.</description>
  </primary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Small Cell Lung Cancer</condition>
  <condition>Small Cell Lung Carcinoma</condition>
  <arm_group>
    <arm_group_label>Phase I</arm_group_label>
    <description>Up to 12 participants with tumors that are found to be &gt;/= 50% positive for DLL3 by IHC</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Phase II</arm_group_label>
    <description>Up to 18 participants with tumors that are found to be &gt;/= 50% positive for DLL3 by IHC</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>89Zr-DFO-SC16.56</intervention_name>
    <description>Injection of 2 mCi of 89Zr-DFO-SC16.56 for Phase I participants. Dose for Phase II will be determined by results from Phase I.</description>
    <arm_group_label>Phase I</arm_group_label>
    <arm_group_label>Phase II</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>SC16.56, Phase I, Cohort 2</intervention_name>
    <description>7.5mg</description>
    <arm_group_label>Phase I</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>SC16.56, Phase I, Cohort 3</intervention_name>
    <description>22.5mg</description>
    <arm_group_label>Phase I</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>SC16.56, Phase II</intervention_name>
    <description>Dose for Phase II will be determined by results from Phase I.</description>
    <arm_group_label>Phase II</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Patients who meet the above inclusion and exclusion criteria will be invited to participate
        in the study by a designated consenting professional, which in most cases is likely to be
        their primary oncologist. Men and women, and all minorities will be considered for
        participation on an equal basis.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Signed, informed consent

          -  Age 18 or more years

          -  Histologically confirmed, extensive stage SCLC or small cell carcinoma of unknown or
             non-lung origin*, defined as disease that has spread beyond the ipsilateral hemithorax
             or which cannot be encompassed within a single radiation port (newly diagnosed or
             recurrent)

          -  At least one tumor lesion on CT or MRI &gt;/= 2 cm

          -  ECOG performance status 0 to 2

          -  Negative serum pregnancy test within 2 weeks of 89Zr- DFO-SC16.56

          -  Adequate organ function as assessed by

          -  Absolute neutrophil count (ANC) &gt;/= 1,500 mm^8

          -  Hemoglobin &gt;/= 9.0 g/dL (in the absence of red blood cell transfusions in the last 2
             weeks)

          -  Platelet count &gt;/= 75,000/mm^3

          -  Bilirubin &lt;/= 1.5 x ULN (upper limit of the norm)

          -  AST (GOT) &lt;/= 2.5 x ULN (when no liver metastases are present)

          -  AST (GOT) &lt;/= 5.0 x ULN (when liver metastases are present)

          -  ALT (GOT) &lt;/= 2.5 x ULN (when no liver metastases are present)

          -  ALT (GOT) &lt;/= 5.0 x ULN (when liver metastases are present)

          -  Creatinine &lt;/= 1.5 x ULN

          -  Available archival tumor biopsy material suitable for DLL3 IHC. Archival tissue is not
             required to have been collected within a specific time frame relative to imaging

               -  Patients with SCLC will be the primary study population, however patients with
                  small cell carcinoma of unknown or non-lung origin may be included at the PI's
                  discretion.

        Exclusion Criteria:

          -  History of anaphylactic reaction to humanize or human antibodies

          -  Pregnant or breast feeding

          -  Psychiatric illness that would interfere with compliance with the study procedures

          -  Active, bacterial, viral or fungal infection requiring systemic therapy

          -  Inability to undergo PET scan due to weight limit

          -  Prior treatment with Rova-T
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mark P Dunphy, DO</last_name>
    <role>Principal Investigator</role>
    <affiliation>Memorial Sloan Kettering Cancer Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Mark P Dunphy, DO</last_name>
    <phone>212-639-8131</phone>
    <email>dunphym@mskcc.org</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Charles Rudin, MD, PhD</last_name>
    <phone>646-888-4527</phone>
    <email>rudinc@mskcc.org</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Memorial Sloan Kettering Cancer Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10065</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mark Dunphy, DO</last_name>
      <phone>212-639-8131</phone>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.mskcc.org</url>
    <description>Memorial Sloan Kettering Cancer Center</description>
  </link>
  <verification_date>April 2020</verification_date>
  <study_first_submitted>December 12, 2019</study_first_submitted>
  <study_first_submitted_qc>December 12, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">December 16, 2019</study_first_posted>
  <last_update_submitted>April 28, 2020</last_update_submitted>
  <last_update_submitted_qc>April 28, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">April 29, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Small cell lung cancer</keyword>
  <keyword>Small Cell Lung Carcinoma</keyword>
  <keyword>89Zr-DFO-SC16.56</keyword>
  <keyword>19-292</keyword>
  <keyword>Memorial Sloan Kettering Cancer Center</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Neoplasms</mesh_term>
    <mesh_term>Small Cell Lung Carcinoma</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Memorial Sloan Kettering Cancer Center supports the international committee of medical journal editors (ICMJE) and the ethical obligation of responsible sharing of data from clinical trials. The protocol summary, a statistical summary, and informed consent form will be made available on clinicaltrials.gov when required as a condition of Federal awards, other agreements supporting the research and/or as otherwise required. Requests for deidentified individual participant data can be made beginning 12 months after publication and for up to 36 months post publication. Deidentified individual participant data reported in the manuscript will be shared under the terms of a Data Use Agreement and may only be used for approved proposals. Requests may be made to: crdatashare@mskcc.org.</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

